XML 192 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity-Based Compensation (Tables)
 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]    
Summary of Compensation Cost Recognized

Presented below is a summary of the compensation cost recognized in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023.

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(in thousands)

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Research and development

 

$

1,206

 

 

$

1,347

 

 

$

3,527

 

 

$

4,803

 

Sales and marketing

 

 

2

 

 

 

87

 

 

 

(5

)

 

 

407

 

General and administrative

 

 

1,949

 

 

 

3,402

 

 

 

5,926

 

 

 

18,563

 

Total

 

$

3,157

 

 

$

4,836

 

 

$

9,448

 

 

$

23,773

 

 

Presented below is a summary of the compensation cost recognized in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2023 and 2022.

 

 

 

Year Ended December 31,

 

 

 

2023

 

 

2022

 

 

 

(in thousands)

 

Research and development

 

$

6,505

 

 

$

1,765

 

Sales and marketing

 

 

507

 

 

 

286

 

General and administrative

 

 

22,932

 

 

 

4,297

 

Total stock-based compensation
   expense

 

$

29,943

 

 

$

6,348

 
Summary of Stock Option Activity

The following summary sets forth the stock option activity under the 2023 and 2020 Plan:

 

 

Number of options

 

 

Weighted average exercise price

 

 

Weighted average remaining contractual term (in years)

 

 

Aggregate intrinsic value (in thousands)

 

Outstanding as of December 31, 2023

 

 

854

 

 

$

10,118.00

 

 

 

9.3

 

 

$

547

 

Granted

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Exercised

 

 

—

 

 

 

—

 

 

 

 

 

 

 

Cancelled or forfeited

 

 

(46

)

 

 

8,428.00

 

 

 

 

 

 

 

Outstanding as of September 30, 2024

 

 

808

 

 

$

10,214.00

 

 

 

8.5

 

 

$

—

 

Options exercisable as of September 30, 2024

 

 

344

 

 

$

6,311.00

 

 

 

8.4

 

 

$

—

 

Options unvested as of September 30, 2024

 

 

491

 

 

$

14,395.00

 

 

 

8.6

 

 

$

—

 

The following summary sets forth the stock option activity under the 2023 and 2020 Plan:

 

 

Number of options

 

 

Weighted average exercise price

 

 

Weighted average remaining contractual term (in years)

 

 

Aggregate intrinsic value (in thousands)

 

Outstanding as of December 31, 2022

 

 

112

 

 

$

9,200.00

 

 

 

9.6

 

 

$

11,706

 

Granted

 

 

938

 

 

 

9,040.00

 

 

 

 

 

 

 

Exercised

 

 

(169

)

 

 

2,120.00

 

 

 

 

 

 

12,690

 

Cancelled or forfeited

 

 

(25

)

 

 

5,200.00

 

 

 

 

 

 

 

Outstanding as of December 31, 2023

 

 

856

 

 

 

10,120.00

 

 

 

9.3

 

 

$

547

 

Options exercisable as of December 31, 2023

 

 

231

 

 

$

6,880.00

 

 

 

9.0

 

 

$

264

 

Options unvested as of December 31, 2023

 

 

640

 

 

$

12,400.00

 

 

 

9.4

 

 

$

299

 
Summary of Unvested Common Stock

A summary of unvested common stock from early option exercises that are subject to repurchase by the Company under the 2020 Plan is as follows:

 

 

Early Option Exercises

 

 

Number of options

 

 

Weighted average exercise price

 

 

Repurchase liability (in thousands)

 

Unvested common stock as of December 31, 2023

 

 

3

 

 

$

—

 

 

$

8

 

Issued

 

 

—

 

 

 

—

 

 

 

—

 

Vested

 

 

(2

)

 

 

—

 

 

 

—

 

Repurchased

 

 

—

 

 

 

—

 

 

 

—

 

Unvested common stock as of September 30, 2024

 

 

1

 

 

 

 

 

$

3

 

A summary of unvested common stock from early option exercises that are subject to repurchase by the Company under the 2020 Plan is as follows:

 

 

Early Option Exercises

 

 

Number of options

 

 

Weighted average exercise price

 

 

Repurchase liability (in thousands)

 

Unvested common stock as of December 31,
   2022

 

 

1

 

 

$

—

 

 

$

306

 

Issued

 

 

6

 

 

 

4,160.00

 

 

 

—

 

Vested

 

 

(3

)

 

 

—

 

 

 

—

 

Repurchased

 

 

(1

)

 

 

—

 

 

 

—

 

Unvested common stock as of December 31,
   2023

 

 

3

 

 

 

 

 

$

8

 
Summary of Stock Option Valuation Assumptions The fair value of each option was estimated at the grant date using the Black-Scholes method with the following assumptions:

 

 

 

September 30,

 

 

September 30,

 

 

2024

 

 

2023

 

Weighted-average risk-free interest rate (1)

 

 

—

%

 

 

3.7

%

Weighted-average expected term (in years)

 

 

—

 

 

 

5.93

 

Weighted-average expected volatility (2)

 

 

—

%

 

 

62.3

%

Expected dividend yield

 

 

—

%

 

 

—

%

 

(1)
Based on U.S. Treasury seven-year constant maturity interest rate whose term is consistent with the expected term of the option.
(2)
Expected volatility is based on an analysis of comparable public company volatilities and adjusted for the Company’s stage of development.
 he fair value of each option was estimated at the grant date using the Black-Scholes method with the following assumptions:

 

 

 

December 31,

 

 

December 31,

 

 

2023

 

 

2022

 

Weighted-average risk-free interest rate (1)

 

 

3.7

%

 

 

3.3

%

Weighted-average expected term (in years)

 

 

5.87

 

 

 

5.35

 

Weighted-average expected volatility (2)

 

 

62.29

%

 

 

54.6

%

Expected dividend yield

 

 

—

%

 

 

—

%

 

(1)
Based on U.S. Treasury seven-year constant maturity interest rate whose term is consistent with the expected term of the option.
(2)
Expected volatility is based on an analysis of comparable public company volatilities and adjusted for the Company’s stage of development.